Spyre Therapeutics (SYRE) Share-based Compensation (2015 - 2026)

Spyre Therapeutics' Share-based Compensation history runs 12 years deep, the most recent figure standing at $12.8 million for Q1 2026.

• Quarterly Share-based Compensation rose 44.55% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.3 million (up 753.61% YoY) and the FY2025 annual result came in at $37.6 million, changed N/A from the prior year.
• Share-based Compensation was $12.8 million for Q1 2026 at Spyre Therapeutics, up from $9.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $181.3 million in Q4 2023 and bottomed at -$35.6 million in Q4 2024.
• A 5-year average of $15.1 million and a median of $7.9 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation surged 2450.15% — and 2024, when it tumbled 119.63%.
• Spyre Therapeutics' Share-based Compensation stood at $7.1 million in 2022, then soared by 2450.15% to $181.3 million in 2023, then tumbled by 119.63% to -$35.6 million in 2024, then jumped by 127.56% to $9.8 million in 2025, then surged by 30.53% to $12.8 million in 2026.
• Business Quant data shows SYRE's Share-based Compensation at $12.8 million in Q1 2026, $9.8 million in Q4 2025, and $300000.0 in Q3 2025.